Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant

被引:6
|
作者
Oh, Sae Jin [1 ]
Sang Won, O. [1 ]
Choi, Yong Jun [1 ]
Kim, Jeong-Min [1 ]
Kim, Dongju [1 ]
Kim, Il-Hwan [1 ]
Park, Ae Kyung [1 ]
Kim, Heui Man [1 ]
Rhee, Jee Eun [1 ]
Jang, Young Rock [3 ]
Yoo, Cheon-Kwon [2 ]
Kim, Jin Yong [3 ]
Kim, Eun-Jin [1 ]
机构
[1] Korea Dis Control & Prevent Agcy KDCA, Bur Infect Dis Diag Control, Div Emerging Infect Dis, 187 Osongsaengmyeong 2 ro,Osong eup, Cheongju 28159, Chungcheongbuk, South Korea
[2] Korea Dis Control & Prevent Agcy, Bur Infect Dis Diag Control, Cheongju, Chungcheongbuk, South Korea
[3] Incheon Med Ctr, Dept Internal Med, Div Infect Dis, 217,Bangchuk ro, Incheon 22532, South Korea
关键词
SARS-CoV-2; Omicron; Neutralizing antibody; Vaccination; Cross; -neutralization;
D O I
10.1016/j.jcv.2022.105253
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: The Omicron variant, with numerous mutations in the spike protein, reduces vaccine-induced immunity, leading to breakthrough infections. However, vaccine protection after infection with the Omicron variant is unclear. Aims and methods: To compare the neutralizing antibody responses between unvaccinated and vaccinated individuals infected with the Omicron variant, we have collected serial plasma samples from five unvaccinated and four vaccinated individuals with Omicron variant infection, including the first Omicron breakthrough infection case in the Republic of Korea. We evaluated neutralization antibody titers against D614G, Delta, and Omicron using live virus neutralizing assay, and calculated the plaque reduction neutralizing test value. Results: In patients with two-dose vaccinations, neutralizing antibodies against Omicron variant were detected in plasma collected 4-9 days post symptom onset. However, in the plasma from unvaccinated patients and those vaccinated with one dose, neutralizing antibodies against the Omicron variant at the same time point were undetectable. Next, the 1-or 2-dose vaccinated infected groups showed potent cross-neutralizing activity against D614G and Delta variants after 11-14 days. In contrast, the neutralizing antibody titers in the unvaccinated group were low or undetectable. Conclusions: The major limitation of this study is the small sample size due to the limited samples targeting the first reported cases of Omicron BA.1 variant infection in the Republic of Korea (n = 9). Nevertheless, we found that vaccinated individuals rapidly produced neutralizing antibodies against Omicron, and potent cross -neutralizing antibodies against D614G and Delta upon infection with Omicron.
引用
收藏
页数:4
相关论文
共 50 条
  • [11] Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals
    Emmelot, Maarten E.
    Vos, Martijn
    Boer, Mardi C.
    Rots, Nynke Y.
    de Wit, Jelle
    van Els, Cecile A. C. M.
    Kaaijk, Patricia
    VIRUSES-BASEL, 2022, 14 (07):
  • [12] The Rise and Fall of Omicron BA.1 Variant as Seen in Wastewater Supports Epidemiological Model Predictions
    Naim, Michal Liddor
    Fu, Yu
    Shagan, Marilou
    Bar-Or, Itay
    Marks, Robert
    Sun, Qun
    Granek, Rony
    Kushmaro, Ariel
    VIRUSES-BASEL, 2023, 15 (09):
  • [13] Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
    Shohei Yamamoto
    Kouki Matsuda
    Kenji Maeda
    Yusuke Oshiro
    Natsumi Inamura
    Tetsuya Mizoue
    Maki Konishi
    Junko S. Takeuchi
    Kumi Horii
    Mitsuru Ozeki
    Haruhito Sugiyama
    Hiroaki Mitsuya
    Wataru Sugiura
    Norio Ohmagari
    BMC Infectious Diseases, 23
  • [14] Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
    Yamamoto, Shohei
    Matsuda, Kouki
    Maeda, Kenji
    Oshiro, Yusuke
    Inamura, Natsumi
    Mizoue, Tetsuya
    Konishi, Maki
    Takeuchi, Junko S.
    Horii, Kumi
    Ozeki, Mitsuru
    Sugiyama, Haruhito
    Mitsuya, Hiroaki
    Sugiura, Wataru
    Ohmagari, Norio
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [15] Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
    Sullivan, David J.
    Franchini, Massimo
    Joyner, Michael J.
    Casadevall, Arturo
    Focosi, Daniele
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [16] Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant
    Gallian, Pierre
    Amroun, Abdennour
    Laperche, Syria
    Le Cam, Sophie
    Brisbarre, Nadege
    Malard, Lucile
    Nurtop, Elif
    Isnard, Christine
    Richard, Pascale
    Morel, Pascal
    Tiberghien, Pierre
    de Lamballerie, Xavier
    VOX SANGUINIS, 2022, 117 (07) : 971 - 975
  • [17] Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
    Yang, Jinyoung
    Won, Gunho
    Baek, Jin Yang
    Lee, Young Ho
    Kim, Haein
    Huh, Kyungmin
    Cho, Sun Young
    Kang, Cheol-In
    Chung, Doo Ryeon
    Peck, Kyong Ran
    Lee, Kyo Won
    Park, Jae Berm
    Yoon, Sang Eun
    Kim, Seok Jin
    Kim, Won Seog
    Yim, Min Su
    Kim, Kwangwook
    Hyeon, Seokhwan
    Kim, Byung Chul
    Lee, Yoo-kyung
    Ko, Jae-Hoon
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [18] The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
    Moulana, Alief
    Dupic, Thomas
    Phillips, Angela M.
    Chang, Jeffrey
    Roffler, Anne A.
    Greaney, Allison J.
    Starr, Tyler N.
    Bloom, Jesse D.
    Desai, Michael M.
    ELIFE, 2023, 12
  • [19] Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
    Dimeglio, Chloe
    Migueres, Marion
    Bouzid, Naemie
    Chapuy-Regaud, Sabine
    Gernigon, Caroline
    Da-Silva, Isabelle
    Porcheron, Marion
    Martin-Blondel, Guillaume
    Herin, Fabrice
    Izopet, Jacques
    VACCINES, 2022, 10 (09)
  • [20] Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
    Ohashi, Hirofumi
    Hishiki, Takayuki
    Akazawa, Daisuke
    Kim, Kwang Su
    Woo, Joohyeon
    Shionoya, Kaho
    Tsuchimoto, Kana
    Iwanami, Shoya
    Moriyama, Saya
    Kinoshita, Hitomi
    Yamada, Souichi
    Kuroda, Yudai
    Yamamoto, Tsukasa
    Kishida, Noriko
    Watanabe, Shinji
    Hasegawa, Hideki
    Suzuki, Tadaki
    Maeda, Ken
    Fukushi, Shuetsu
    Takahashi, Yoshimasa
    Iwami, Shingo
    Watashi, Koichi
    ANTIVIRAL RESEARCH, 2022, 205